FilingSEC EDGAR8-K
Jasper Therapeutics Completes Enrollment in IgAN Phase 2 Cohort
· SEC accepted
StagePhase 2
Filing content
The company completed enrollment for the IgAN cohort of its Phase 2 basket study and expects to report initial interim data by year-end 2026. It also added an FSGS cohort with first dosing anticipated in Q1 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…